GlassScriptPhysician profile
Erica Estep Campbell
NPI 1407418650
$8,088.82
in general payments reported to CMS, 2019-2025
24 companies · $2,977 in 2025
The $2,977 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $394 · 2021: $170 · 2022: $721 · 2023: $631 · 2024: $2,843 · 2025: $2,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,441 · Education: $9.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,441.39 |
| Education | $9.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,273.86 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $910.32 | 2020-2025 | Ingrezza |
| Abbvie INC. | $903.93 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $836.12 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $750.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $712.12 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $501.91 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $437.77 | 2020-2025 | Spravato, Invega, Invega Trinza |
| Indivior INC. | $285.54 | 2022-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $265.58 | 2025 | Cobenfy |
| Tempus Ai, INC | $192.90 | 2024 | |
| Braeburn INC. | $186.06 | 2023-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $174.55 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $108.97 | 2019 | |
| Lundbeck LLC | $102.28 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $96.69 | 2023-2024 | Trintellix |
| American Orthodontics Corporation | $95.09 | 2022 | |
| Allergan, INC. | $79.57 | 2019 | |
| Supernus Pharmaceuticals, INC. | $56.86 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $35.60 | 2022 | |
| Almatica Pharma LLC | $31.34 | 2022-2024 | Loreev Xr |
| Tris Pharma INC | $20.87 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $16.26 | 2023 | Quviviq |
| Corium, LLC | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.